defined as an article," Christelle Legault, a media relations officer with Health Canada, wrote in an email.
"The effect of the definition is that any manufacturer must file a New Drug Submission with information on the quality, safety and efficacy of the maggots for the uses and under the conditions of use recommended. Health Canada has started to work on guidelines to address the regulatory requirements."
Health Canada had previously labelled medicinal maggots as medical devices, says Pearson. In the United States, where the Food and Drug Administration endorsed maggots for wound care in 2004, maggots are still considered prescription-only medical devices, according to Monarch Labs' website (www.monarchlabs.com).
Because of the new Health Canada classification, it now takes Canadian clinicians up to three weeks to get maggots from California. The paperwork and added hassle have prompted some people to abandon maggot therapy, says Pearson, a registered nurse and board member of the Canadian Association of Wound Care. "It's just too onerous, and it's less cost-effective when it takes so long to get them."
Pearson says Canadian parties have also applied to Health Canada for permission to manufacture and sell maggots for wound care. The University of British Columbia in Vancouver had offered space, she says, and Monarch Labs was willing to supply start-up stock. But Health Canada did not grant permission. Canadian wound clinicians are finding it difficult to obtain maggots for larval therapy.
"Health Canada has had several enquiries on the manufacture and sale of maggots. Anyone wishing to sell maggots cannot do so without having a market authorization, which is the case with any other drug product in Canada," Legault wrote.
"Those wishing to use maggots as a form of treatment can also do this via Clinical Trials. While there are no requirements in Canada to undertake Canadian studies before a submission can be filed, it is important to note that studies, international or domestic, will need to be conducted supporting the safety and efficacy for the marketing of a product for treatment purposes."
Though advocates for maggot therapy say research shows it can save 40%-50% of limbs with nonhealing wounds that would have otherwise been amputated, other wound care experts note that only two clinical trials on the treatment have been published.
One found that maggots were more effective than standard treatment, hydrogel, in debriding wounds (J Tissue Viability 2000;10:91-4). The other concluded that, while superior for debridement, maggot therapy was no better than hydrogel at increasing healing rates or decreasing bacteria (BMJ 2009; 338:b773) . -Roger Collier, CMAJ DOI:10.1503/cmaj.109-3134 
